Current assets: |
Cash and cash equivalents |
33.12M |
Investments in marketable securities |
179.28M |
Receivable due from GSK |
Prepaid expenses and other current assets |
Total current assets |
221.71M |
Property and equipment, accumulated depreciation and amortization of $8,095 and $8,959 at December 31, 2010 and June 30, 2011, respectively |
10.18M |
Other non-current assets |
1.79M |
Total Assets |
918.18M |
Current liabilities: |
Accounts payable and accrued expenses |
29.01M |
Current portion of capital lease obligations |
Current portion of deferred revenue |
Current portion of secured loan |
Total current liabilities |
85.61M |
Deferred revenue, less current portion |
Warrant liability |
Secured loan, less current portion |
Commitments and contingencies |
0 |
Stockholders' equity: |
Common stock, $.01 par value, 50,000,000 shares authorized, 34,508,932 shares issued and outstanding at December 31, 2010, 50,000,000 shares authorized, 34,596,809 shares issued and outstanding at June 30, 2011 |
1.48M |
Additional paid-in capital |
1.04B |
Accumulated other comprehensive loss |
Deficit accumulated during the development stage |
-720.96M |
Total stockholders' equity |
336.56M |
Total Liabilities and Stockholders' Equity |
918.18M |